SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+93.8%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$643M
AUM Growth
+$643M
(+97%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
18.4%
Top 10 Holdings %
Top 10 Hldgs %
78.08%
Holding
44
New
3
Increased
4
Reduced
5
Closed
3
Top Buys
| 1 |
CRGX
CARGO Therapeutics
CRGX
|
$95.4M |
| 2 |
Scholar Rock
SRRK
|
$41.2M |
| 3 |
Neurogene
NGNE
|
$24.6M |
| 4 |
ABVX
Abivax
ABVX
|
$9.1M |
| 5 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$7.05M |
Top Sells
| 1 |
vTv Therapeutics
VTVT
|
$18.3M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$11.9M |
| 3 |
Arcellx
ACLX
|
$8.52M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$7.94M |
| 5 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$4.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$3.14B
| $128M | 19.85% | 6,788,609 +2,189,781 | +48% | +$41.2M |
|
|
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $115M | 17.85% | 1,845,948 | – | – |
|
|
CRGX
3
DELISTED
CARGO Therapeutics
CRGX
| $95.4M | 14.84% | +4,121,689 | New | +$95.4M |
|
4
Mineralys Therapeutics
MLYS
$1.03B
| $38.9M | 6.05% | 4,519,361 | – | – |
|
|
5
Arcellx
ACLX
$3.85B
| $25.6M | 3.98% | 460,441 -153,480 | -25% | -$8.52M |
|
|
6
Neurogene
NGNE
$264M
| $24.6M | 3.82% | +1,267,790 | New | +$24.6M |
|
|
LENZ
7
LENZ Therapeutics
LENZ
$1.1B
| $22.2M | 3.45% | 8,459,314 | – | – |
|
8
Nkarta
NKTX
$151M
| $18.9M | 2.94% | 2,868,035 | – | – |
|
|
SLRN
9
DELISTED
ACELYRIN
SLRN
| $18.8M | 2.93% | 2,523,022 +141,443 | +6% | +$1.06M |
|
10
Zymeworks
ZYME
$1.12B
| $15.2M | 2.36% | 1,458,875 | – | – |
|
11
Lyra Therapeutics
LYRA
$11.5M
| $14.6M | 2.27% | 2,780,261 | – | – |
|
|
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $13.9M | 2.16% | 1,786,427 +904,977 | +103% | +$7.05M |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.43B
| $13.7M | 2.13% | 967,527 | – | – |
|
14
HilleVax
HLVX
$105M
| $12.8M | 2% | 799,274 | – | – |
|
|
ABVX
15
Abivax
ABVX
$6.12B
| $9.1M | 1.41% | +850,000 | New | +$9.1M |
|
|
16
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.94M | 1.23% | 172,647 -172,646 | -50% | -$7.94M |
|
17
Sutro Biopharma
STRO
$72.7M
| $7.19M | 1.12% | 1,675,579 | – | – |
|
|
VRNA
18
Verona Pharma
VRNA
$9.16B
| $6.91M | 1.07% | 347,500 | – | – |
|
19
IO Biotech
IOBT
$104M
| $6.84M | 1.06% | 3,640,015 | – | – |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $6.66M | 1.04% | 1,562,500 | – | – |
|
21
Tango Therapeutics
TNGX
$747M
| $6.24M | 0.97% | 630,000 | – | – |
|
22
Gossamer Bio
GOSS
$562M
| $5.59M | 0.87% | 6,130,268 | – | – |
|
23
Immatics
IMTX
$619M
| $4.17M | 0.65% | 396,000 | – | – |
|
24
Prime Medicine
PRME
$578M
| $4.17M | 0.65% | 470,304 | – | – |
|
25
Janux Therapeutics
JANX
$1.37B
| $3.87M | 0.6% | 360,414 | – | – |
|